Cite

HARVARD Citation

    Camidge, D. et al. (n.d.). 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study. European journal of cancer. pp. S616-. [Online]. 
  
Back to record